Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19.
10.1016/j.apsb.2020.04.008
- Author:
Xiaoyan LIU
1
;
Zhe LI
2
;
Shuai LIU
1
;
Jing SUN
3
;
Zhanghua CHEN
4
;
Min JIANG
5
;
Qingling ZHANG
3
;
Yinghua WEI
5
;
Xin WANG
6
;
Yi-You HUANG
2
;
Yinyi SHI
7
;
Yanhui XU
4
;
Huifang XIAN
4
;
Fan BAI
8
;
Changxing OU
3
;
Bei XIONG
1
;
Andrew M LEW
9
;
Jun CUI
10
;
Rongli FANG
4
;
Hui HUANG
11
;
Jincun ZHAO
3
;
Xuechuan HONG
12
;
Yuxia ZHANG
4
;
Fuling ZHOU
1
;
Hai-Bin LUO
2
Author Information
1. Department of Hematology, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.
2. Guangdong Provincial Key Laboratory of New Drug Design and Evaluation, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.
3. State Key Laboratory of Respiratory Diseases, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China.
4. Guangzhou Institute of Pediatrics, Guangzhou Women and Children's Medical Center, State Key Laboratory of Respiratory Diseases, Guangzhou Medical University, Guangzhou 510623, China.
5. Department of Infectious Disease and Department of Pediatrics, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China.
6. Center for Innovative Marine Drug Screening & Evaluation (QNLM), School of Medicine and Pharmacy, Ocean University of China, Qingdao 266100, China.
7. Dawu County People's Hospital, Xiaogan 432826, China.
8. Biomedical Pioneering Innovation Center (BIOPIC), School of Life Sciences, Peking University, Beijing 100871, China.
9. Walter and Eliza Hall Institute of Medical Research and Department of Microbiology & Immunology, University of Melbourne, Parkville, Vic 3052, Australia.
10. School of Life Sciences, Sun Yat-sen University, Guangzhou 510006, China.
11. Cardiovascular Department, The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen 518000, China.
12. State Key Laboratory of Virology, College of Science, Innovation Center for Traditional Tibetan Medicine Modernization and Quality Control, Medical College, Tibet University, Lhasa 850000, China.
- Publication Type:Journal Article
- Keywords:
COVID-19;
D-dimer;
Dipyridamole;
SARS-CoV-2;
Severe cases;
Treatment
- From:
Acta Pharmaceutica Sinica B
2020;10(7):1205-1215
- CountryChina
- Language:English
-
Abstract:
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can cause acute respiratory distress syndrome, hypercoagulability, hypertension, and multiorgan dysfunction. Effective antivirals with safe clinical profile are urgently needed to improve the overall prognosis. In an analysis of a randomly collected cohort of 124 patients with COVID-19, we found that hypercoagulability as indicated by elevated concentrations of D-dimers was associated with disease severity. By virtual screening of a U.S. FDA approved drug library, we identified an anticoagulation agent dipyridamole (DIP) , which suppressed SARS-CoV-2 replication . In a proof-of-concept trial involving 31 patients with COVID-19, DIP supplementation was associated with significantly decreased concentrations of D-dimers ( < 0.05), increased lymphocyte and platelet recovery in the circulation, and markedly improved clinical outcomes in comparison to the control patients. In particular, all 8 of the DIP-treated severely ill patients showed remarkable improvement: 7 patients (87.5%) achieved clinical cure and were discharged from the hospitals while the remaining 1 patient (12.5%) was in clinical remission.
